Dr. H.C. Lui, Director of Eagle IP Limited, and Mr. Stephen Ko, US Registered Patent Agent, gave a talk on “Introduction to Patent Protection in the US” at the Macau University of Science and Technology.
我們過去活動
Recommended Insights
China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux
2021年5月24日The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]
閱讀更多 >
Breaking News: China passes Fourth Amendment to the Chinese Patent Law
2020年10月19日After 12 years, the Fourth Amendment to the Chinese Patent Law has passed and will be in effect on 1 Jun 2021. After years of multiple draft amendments that moved in various directions, we FINALLY have some clarity on what patent protection is going to look like in China in the coming future. Many of […]
閱讀更多 >
Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?
2020年7月14日This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]
閱讀更多 >
China Releases Draft Implementation Guidelines for the Drug Administration Law
2022年6月2日The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]
閱讀更多 >